cagrilintide 5mg+semaglutide 5mg Semaglutide + Blend (Research) Cagrilintide 5mg Peptide | High

However, clinical trials of the combination therapy have not shown an increase in depression or suicidality compared to placebo

Retatrutide is the newest entrant, a triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously

Until such studies are conducted, the combination remains investigational and should be approached with appropriate caution, written informed consent, and consideration of FDA MedWatch reporting for any adverse events that occur with off-label combination use

Do not stop Ozempic without medical advice, as abrupt cessation may adversely affect your blood glucose control